Australia markets closed

Cosmos Holdings Inc. (COSM)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.1500-0.1500 (-3.49%)
At close: 3:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3000
Open4.1700
Bid0.0000 x 0
Ask0.0000 x 0
Day's range4.0000 - 4.2000
52-week range2.1300 - 7.7700
Volume9,429
Avg. volume15,275
Market cap71.871M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-0.3220
Earnings date18 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    UPDATE - Cosmos Holdings Secures Approximately $5.5 Million Investment from Ault Global Holdings

    Received initial bridge financing for proceeds of approximately $500,000 plus an additional $5.0 million of Series A Preferred Stock upon approval of Nasdaq listingCHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, through an extensive, established European Union

  • GlobeNewswire

    Cosmos Holdings Secures Approximately $5.5 Million Investment from Ault Global Holdings

    Received initial bridge financing for proceeds of approximately $500,000 plus an additional $5.0 million of Series A Preferred Stock upon approval of Nasdaq listingCHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, through an extensive, established European Union

  • GlobeNewswire

    Cosmos Holdings Announces Voluntary Conversion of Debt to Equity by the Company’s Senior Lender, Further Enhancing the Balance Sheet

    CHICAGO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, and an extensive, established European Union distribution network, today announced that the Company has entered into a debt exchange agreement with its senior lender (Lender) to further reduce the Company’s debt. Under the terms of the agreement,